Canopy Growth (CGC) Q1 Revenue Jumps 9%

Canopy Growth (NASDAQ:CGC), a major player in the global cannabis industry known for its medical, adult-use, and vaporizer products, announced its financial results for Q1 FY2026 (prepared in accordance with U.S. GAAP) on August 8, 2025. The most noteworthy headline was a significant outperformance on revenue, reaching $72.1 million compared to analyst expectations of $49.8 million. However, the quarter also saw gross margin compression and wider adjusted EBITDA losses. The period showed early signs of progress in core Canadian cannabis segments, but profitability and margin recovery remain ongoing challenges. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q4 2025 earnings report. The company operates across cannabis cultivation, production, and distribution, serving both medical and adult-use (recreational) markets. It also owns the Storz & Bickel brand, producing premium vaporization devices for both medical and recreational consumers. Core operations span Canada, Europe, and Australia, with strategic exposure to the U.S. market via investments in Canopy USA.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool